Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.

Journal of Alzheimer's disease : JAD - 1 Jan 2017

Voyle Nicola, Patel Hamel, Folarin Amos, Newhouse Stephen, Johnston Caroline, Visser Pieter Jelle, Dobson Richard J B, Kiddle Steven J

Abstract excerpt

BACKGROUND: The search for a biomarker of Alzheimer's disease (AD) pathology (amyloid-β (Aβ) and tau) is ongoing, with the best markers currently being measurements of Aβ and tau in cerebrospinal fluid (CSF) and via positron emission tomography (PET) scanning. These methods are relatively invasive, costly, and often have high screening failure rates. Consequently, research is aiming to elucidate blood biomarkers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Factual

Share to Early Diagnosis

Share to Logistic Models

Share to Oligonucleotide Array Sequence Analysis

Share to Positron-Emission Tomography

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27834776
DOI: 10.3233/JAD-160707
PMCID: PMC5181674

Genes

EDAR
APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.PMID 27834776Read ↗

Does genetic risk help to predict amyloid burden in a non-demented population? A Bayesian approachSemantic proximity Read ↗

Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.Semantic proximity Read ↗

A/T/N polygenic risk score for cognitive decline in old ageSemantic proximity Read ↗

Shared genetic background between cerebrospinal fluid biomarkers and risk for Alzheimer’s disease: A two-sample Mendelian randomisation studySemantic proximity Read ↗

A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42.Semantic proximity Read ↗

Genetic architecture of plasma Alzheimer disease biomarkersSemantic proximity Read ↗

Genetic risk for Alzheimer’s disease influences neuropathology and cognition via multiple biological pathwaysSemantic proximity Read ↗

Endophenotype-based polygenic risk scores: Prediction of biomarker and clinical progression and dementiaSemantic proximity Read ↗

Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid.Semantic proximity Read ↗

Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s diseaseSemantic proximity Read ↗

A genetics‐based biomarker risk algorithm for predicting risk of Alzheimer's diseaseSemantic proximity Read ↗

Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer's DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.